日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱(chēng) 貨號(hào) 規(guī)格
Recombinant Bacillus subtilis HTH-type transcriptional activator mta (mta) CSB-YP300298BRJ
CSB-EP300298BRJ
CSB-BP300298BRJ
CSB-MP300298BRJ
CSB-EP300298BRJ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bacillus subtilis Putative HTH-type transcriptional regulator ywgB (ywgB) CSB-YP300299BRJ
CSB-EP300299BRJ
CSB-BP300299BRJ
CSB-MP300299BRJ
CSB-EP300299BRJ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bacillus subtilis Putative glycosyltransferase epsH (epsH) CSB-YP300300BRJ
CSB-EP300300BRJ
CSB-BP300300BRJ
CSB-MP300300BRJ
CSB-EP300300BRJ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bacillus subtilis Uncharacterized protein yukC (yukC), partial CSB-YP300301BRJ1
CSB-EP300301BRJ1
CSB-BP300301BRJ1
CSB-MP300301BRJ1
CSB-EP300301BRJ1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bacillus subtilis Putative multidrug export ATP-binding/permease protein YgaD (ygaD), partial CSB-YP300302BRJ1
CSB-EP300302BRJ1
CSB-BP300302BRJ1
CSB-MP300302BRJ1
CSB-EP300302BRJ1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Protein traM (traM) CSB-YP300303ENL
CSB-EP300303ENL
CSB-BP300303ENL
CSB-MP300303ENL
CSB-EP300303ENL-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli Colanic acid biosynthesis protein wcaK (wcaK) CSB-YP300304ENV
CSB-EP300304ENV
CSB-BP300304ENV
CSB-MP300304ENV
CSB-EP300304ENV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli Uncharacterized deacetylase yaiS (yaiS) CSB-YP300305ENV
CSB-EP300305ENV
CSB-BP300305ENV
CSB-MP300305ENV
CSB-EP300305ENV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Haemophilus influenzae Fe (3+)-transport system permease protein fbpB 2, partial CSB-YP300306HTA
CSB-EP300306HTA
CSB-BP300306HTA
CSB-MP300306HTA
CSB-EP300306HTA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Haemophilus influenzae Thiamine-phosphate synthase (thiE) CSB-YP300307HTA
CSB-EP300307HTA
CSB-BP300307HTA
CSB-MP300307HTA
CSB-EP300307HTA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Haemophilus influenzae Putative antitoxin RelB (relB) CSB-YP300308HTA
CSB-EP300308HTA
CSB-BP300308HTA
CSB-MP300308HTA
CSB-EP300308HTA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Haemophilus influenzae Uncharacterized permease HI_1015 (HI_1015), partial CSB-YP300309HTA
CSB-EP300309HTA
CSB-BP300309HTA
CSB-MP300309HTA
CSB-EP300309HTA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Haemophilus influenzae Protein licA (licA) CSB-YP300310HTA
CSB-EP300310HTA
CSB-BP300310HTA
CSB-MP300310HTA
CSB-EP300310HTA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Haemophilus influenzae Lsg locus putative protein 4 (HI_1697) CSB-YP300311HTA
CSB-EP300311HTA
CSB-BP300311HTA
CSB-MP300311HTA
CSB-EP300311HTA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Phosphoribosyl-dephospho-CoA transferase (mdcG) CSB-YP300312KBG
CSB-EP300312KBG
CSB-BP300312KBG
CSB-MP300312KBG
CSB-EP300312KBG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methylobacterium extorquens Dihydroneopterin aldolase (folB) CSB-YP300313MSZ
CSB-EP300313MSZ
CSB-BP300313MSZ
CSB-MP300313MSZ
CSB-EP300313MSZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Uncharacterized protein Rv0964c/MT0992.1 (Rv0964c, MT0992.1) CSB-YP300314MVZ
CSB-EP300314MVZ
CSB-BP300314MVZ
CSB-MP300314MVZ
CSB-EP300314MVZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant UPF0232 protein Rv0004/MT0004 (Rv0004, MT0004) CSB-YP300315MVZ
CSB-EP300315MVZ
CSB-BP300315MVZ
CSB-MP300315MVZ
CSB-EP300315MVZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Uncharacterized protein Rv0026/MT0029 (Rv0026, MT0029) CSB-YP300316MVZ
CSB-EP300316MVZ
CSB-BP300316MVZ
CSB-MP300316MVZ
CSB-EP300316MVZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Riboflavin biosynthesis protein RibD (ribD) CSB-YP300317MVZ
CSB-EP300317MVZ
CSB-BP300317MVZ
CSB-MP300317MVZ
CSB-EP300317MVZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過(guò)多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開(kāi)發(fā)過(guò)程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來(lái)自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開(kāi)發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來(lái)產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過(guò)多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過(guò)程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來(lái)選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見(jiàn)問(wèn)題。您可以單擊以下鏈接查看。http://m.bdspa.cn/technology-91.html。此外,我們還為我們的客戶(hù)提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問(wèn),涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€(xiàn)留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>



×